Effector Therapeutics Inc 's

• EFTR's Stock Performance relative to its Competitors

Madrigal Pharmaceuticals Inc Share Performance +0.03% This Quarter

Madrigal Pharmaceuticals Inc Profile Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas. More about Madrigal Pharmaceuticals Inc 's Market Share

Pyxis Oncology Inc Share Performance +8.78% 30 Days

Pyxis Oncology Inc Profile Pyxis Oncology Inc is a biotechnology company focused on developing innovative cancer therapies. Their business model revolves around leveraging novel insights into the immune system to develop a pipeline of potential immunotherapies for cancer treatment. Pyxis Oncology aims to collaborate with strategic partners to advance their therapies through preclinical and clinical development, ultimately aiming to improve patient outcomes in the field of oncology. More about Pyxis Oncology Inc 's Market Share

Janux Therapeutics Inc Share Performance -11.18% 30 Days

Janux Therapeutics Inc Profile Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market. More about Janux Therapeutics Inc 's Market Share

United Therapeutics Corporation Share Performance -1.47% This Year

United Therapeutics Corporation Profile United Therapeutics Corporation's business model revolves around the development and commercialization of innovative therapeutics for treating rare diseases and chronic conditions. They focus on researching, manufacturing, marketing, and distributing their specialized pharmaceutical and medical products to healthcare providers and patients globally. More about United Therapeutics Corporation's Market Share

Ligand Pharmaceuticals Incorporated Share Performance +8.43% Over The Past 5 Days

Ligand Pharmaceuticals Incorporated Profile Ligand Pharmaceuticals Inc operates on a business model focused on discovering and acquiring new drugs and technologies to license them to pharmaceutical companies. They generate revenue through licensing fees, milestone payments, and royalties from the sales of their partnered products. Their approach allows them to leverage their expertise and resources while minimizing risk, ultimately leading to long-term value creation for their shareholders. More about Ligand Pharmaceuticals Incorporated's Market Share

Sources: Effector Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Friday, September 18, 2026 5:33 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Effector Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.